English, Article edition: The Case of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis Jan Sorensen; Lis S. Andersen

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119403
Physical Description
  • article
Language
  • English

Edition details

Title
  • The Case of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis
Author
  • Jan Sorensen
  • Lis S. Andersen
Physical Description
  • article
Notes
  • Background: Treatment with tumour necrosis factor (TNF)-alpha inhibitors offers promising new opportunities to improve the health-related QOL of patients with rheumatoid arthritis (RA) in Denmark. As of September 2003, two such compounds - infliximab and etanercept - were registered for use by patients with RA. These drugs have shown the ability to reduce disease activity and to slow down or halt the development of new joint damage in otherwise treatment-resistant patients with RA. The acquisition cost of the drugs is high, with 1 year of treatment costing _9000-12_000 per patient. Objective: The aim of this study was to assess the potential impact on the Danish healthcare budget of prescribing infliximab or etanercept to patients with RA. Method: Two treatment implementation scenarios were investigated. In the progressive scenario, all patients newly diagnosed with RA were offered TNFalpha inhibitors as the drug of first choice. In the modest scenario, only patients with insufficient disease suppression by conventional therapy with disease-modifying anti-rheumatic drugs (DMARDs) were offered TNFalpha inhibitor therapy. The budget impact analysis, which was part of a Danish health technology assessment of TNFalpha inhibitors, focused on the number of patients offered treatment during a 5-year period and resource use related to drug and staff costs. Simple sensitivity analyses assessed the consequences of changing the drug dosage, the number of patients offered treatment and the rate of treatment cessation. Results: The results suggested that both implementation strategies would impose additional costs per year on the Danish healthcare service, in the range of _67-188 million for the progressive scenario and _17-49 million for the modest scenario (price level August 2002). These costs represent between half and up to five times the amount currently used on treating patients with RA. Conclusion: This analysis suggests that the introduction of TNFalpha inhibitors into the treatment regimen of patients with RA could pose a considerable financial burden on the Danish healthcare system.
  • Cost-analysis, Disease-modifying-antirheumatics, Etanercept, Infliximab, Rheumatoid-arthritis, Tumour-necrosis-factor-antagonists
  • RePEc:wkh:phecon:v:23:y:2005:i:3:p:289-298
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment